Peanut Allergy Treatment Market Size & Growth Forecast 2026–2035, By Segments (Route of Administration, Distribution Channel, Drug Class), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Peanut Allergy Treatment Market size stood at USD 577.88 Million in 2025 and is predicted to grow at a 11.7% CAGR from 2026 to 2035, reaching USD 1.75 Billion by 2035. The industry revenue for 2026 is calculated at USD 638.23 million.

• Base Year Value (2025): USD 577.88 Million
• CAGR (2026-2035): 11.7%
• Forecast Year Value (2035): USD 1.75 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Peanut Allergy Treatment Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America accounted for 39.55% of the market in 2025, driven by established diagnosis pathways, broad specialist access, strong treatment awareness, and consistent adoption of clinically managed therapies.
  • Asia Pacific is projected to grow at a 13.1% CAGR, supported by expanding healthcare infrastructure, greater specialist access, improved allergy recognition, and increasing adoption of structured clinical treatment.

• Segment Momentum:

  • Injectable treatments accounted for 59.87% of the market in 2025 due to their established role in physician-supervised allergy care, particularly for acute intervention and clinically monitored treatment pathways.
  • Retail pharmacy is the fastest-growing channel as patients increasingly seek convenient access to ongoing therapies and refill-based allergy treatment outside hospital-centered care environments.

• Market Expansion Drivers:

  • Rising peanut allergy prevalence increasing demand for immunotherapy and emergency treatment solutions.
  • Expansion of oral immunotherapy and biologics improving long-term allergy management outcomes.
  • Increased pediatric allergy screening and diagnostic advancements expanding treated patient population.

• Leading Market Participants:

  Key players in the peanut allergy treatment market include Sanofi S.A. (France), Nestlé Health Science S.A. (Switzerland), DBV Technologies S.A. (France), ALK-Abelló A/S (Denmark), Genentech, Inc. (United States), Prota Therapeutics Pty Ltd. (Australia), Aravax Pty Ltd. (Australia), Camallergy Ltd. (United Kingdom), Stallergenes Greer International AG (Switzerland).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 577.88 Million
  • Projected Market Size: USD 1.75 Billion by 2035
  • Growth Forecasts: 11.7% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Injectable (Route of Administration) | Hospital Pharmacy (Distribution Channel) | Epinephrine (Drug Class)
  • Emerging Opportunity Segment: Oral (Route of Administration) | Retail Pharmacy (Distribution Channel) | Immunotherapies (Drug Class)

Market Growth Drivers and Industry Trends

Rising peanut allergy prevalence increasing demand for immunotherapy and emergency treatment solutions

As diagnosed peanut allergy becomes more common, treatment decisions are shifting from avoidance-only strategies toward active clinical management, increasing demand for the peanut allergy treatment market. A larger patient pool increases routine prescribing of epinephrine rescue products while also pushing allergists, pediatricians, and caregivers to consider immunotherapy earlier, especially for children facing ongoing exposure risk in schools and shared food environments. This rise in case volume also changes provider behavior, with specialty clinics expanding capacity for supervised treatment initiation and follow-up, reinforcing market demand for both long-term desensitization options and emergency interventions used in day-to-day allergy management.

Expansion of oral immunotherapy and biologics improving long-term allergy management outcomes

The broader availability of oral immunotherapy and biologic-based approaches is reshaping the peanut allergy treatment market by making long-term management more clinically actionable rather than purely precautionary. Oral immunotherapy creates a structured treatment pathway that requires diagnosis, dose escalation, maintenance, and monitoring, which supports recurring product utilization and deeper engagement between patients and allergy specialists. At the same time, biologics are influencing market adoption by offering options for patients who may not tolerate conventional desensitization well or who need more individualized care, prompting providers to segment treatment choices more actively and encouraging market growth through a more diversified therapeutic landscape.

Increased pediatric allergy screening and diagnostic advancements expanding treated patient population

Earlier and more accurate identification of peanut allergy is enlarging the addressable base for the peanut allergy treatment market by moving more children from suspected allergy status into confirmed care pathways. Pediatric screening, component-resolved diagnostics, and improved referral patterns help clinicians distinguish true peanut allergy from sensitization alone, which reduces uncertainty around treatment eligibility and increases confidence in initiating immunotherapy or prescribing emergency medications. This practical shift matters because treatment uptake often depends on diagnosis clarity; as more children are identified before severe accidental exposures occur, physicians and families are more likely to pursue proactive management, contributing to market size growth through earlier intervention.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising peanut allergy prevalence increasing demand for immunotherapy and emergency treatment solutions	2.00%	High	North America, Asia Pacific	High	Near Term
Expansion of oral immunotherapy and biologics improving long-term allergy management outcomes	1.60%	High	North America, Europe	High	Mid Term
Increased pediatric allergy screening and diagnostic advancements expanding treated patient population	1.40%	High	North America, Europe, Asia Pacific	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 39.55% share of the peanut allergy treatment market in 2025, backed by established allergy diagnosis pathways, broad specialist access, and earlier adoption of clinically managed treatment options. The region’s leadership is strengthened by a healthcare environment where patients are more likely to move from diagnosis to active treatment under allergist supervision, which sustains prescription volumes and follow-up care. Strong awareness among caregivers and clinicians also supports routine identification of peanut allergy cases, helping maintain steady demand through formal treatment channels rather than reliance on avoidance strategies alone.

Asia Pacific is projected to expand at a 13.1% CAGR over the forecast period, driven by improving recognition of food allergies and a gradual shift toward structured clinical management in larger healthcare markets across the region. Growth in the peanut allergy treatment market is being impelled by rising access to specialist care, expanding urban healthcare infrastructure, and increasing willingness among families to seek intervention beyond basic dietary avoidance. As diagnosis becomes more consistent and treatment availability broadens, adoption is accelerating in practice through greater engagement with hospital-based and specialist-led allergy care.

Key Country Insights

United States

Early Intervention Adoption

The U.S. peanut allergy treatment market is benefiting from growing awareness of food allergies and increased acceptance of therapeutic interventions for pediatric patients. Healthcare providers in the U.S. are focusing on earlier diagnosis and structured treatment pathways that improve long-term management.

Japan

Pediatric Management Emphasis

Japan is placing greater attention on pediatric food allergy management, creating opportunities for treatments that reduce the burden on affected families. Healthcare stakeholders in Japan are carefully evaluating therapies that demonstrate safety and support gradual desensitization approaches.

South Korea

Clinical Awareness Expansion

South Korea is experiencing rising clinical attention toward food allergies and improved identification of peanut-sensitive patients. The market in South Korea is increasingly focused on expanding access to therapeutic options and strengthening physician education around allergy management.

Germany

Specialized Care Pathways

Germany is strengthening allergy management through specialist clinics and standardized treatment protocols for peanut allergy patients. Demand in Germany increasingly centers on therapies that can be integrated into supervised care programs and long-term patient monitoring.

France

Structured Allergy Programs

France supports peanut allergy treatment through coordinated care models involving allergists and patient education initiatives. Interest in France is growing for therapies that can complement dietary management and reduce the risk of severe allergic reactions.

Italy

Patient Monitoring Focus

Italy's peanut allergy treatment market is characterized by increasing attention to long-term patient monitoring and individualized care strategies. Healthcare providers in Italy are seeking treatment approaches that improve adherence and support safer management of food allergy risks.

Segment Leadership and Growth Trends

  Route of Administration Segment Analysis: Injectable (Largest Segment) vs Oral (Fastest-Growing Segment)

Within the peanut allergy treatment market, Injectable held the leading position in 2025 with a 59.87% share. Its leadership is supported by the established role of physician-directed treatment pathways in allergy care, especially where controlled dosing, acute intervention needs, and clinical supervision remain central to patient management. Injectable formats also align well with hospital and specialist prescribing patterns, which helps sustain their share across cases where reliability, speed of administration, and established treatment protocols are prioritized.

Oral is the fastest-growing route of administration in the peanut allergy treatment market as demand shifts toward treatment approaches that fit more easily into ongoing, day-to-day management. Growth is being supported by rising interest in less invasive administration and by the practical appeal of therapies that can be integrated into longer-term care outside procedure-based settings. Compared with injectable options, oral treatment is gaining momentum because it better matches evolving patient and caregiver preferences for convenience and routine adherence in allergy management.

Distribution Channel Segment Analysis: Hospital Pharmacy (Largest Segment) vs Retail Pharmacy (Fastest-Growing Segment)

Hospital Pharmacy accounted for the largest position in the peanut allergy treatment market in 2025, holding a 58.23% share. This channel’s leadership reflects the clinical nature of peanut allergy treatment, where diagnosis, initiation of therapy, and management of adverse reactions often remain closely tied to hospital-based care environments. Hospital pharmacies benefit from direct integration with allergists, pediatric specialists, and monitored treatment settings, which helps preserve their share in dispensing therapies that require tighter oversight and coordinated care.

Retail Pharmacy is the fastest-growing distribution channel in the peanut allergy treatment market, influenced by the increasing need for easier access to ongoing therapy and refill-based treatment models. Its momentum comes from the practical advantage of broader consumer reach and greater convenience for patients managing peanut allergy treatment outside hospital settings. Relative to hospital pharmacy channels, retail pharmacy is expanding faster because it is better positioned to support routine access, repeat dispensing, and more decentralized treatment follow-through.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Route of Administration	Oral, Injectable, Others	Injectable	Oral
Distribution Channel	Hospital Pharmacy, Retail Pharmacy, Others	Hospital Pharmacy	Retail Pharmacy
Drug Class	Antihistamines, Epinephrine, Immunotherapies, Others	Epinephrine	Immunotherapies

Competitive Landscape and Market Positioning

Top players in the peanut allergy treatment market:

1. Sanofi S.A. (France)

2. Nestlé Health Science S.A. (Switzerland)

3. DBV Technologies S.A. (France)

4. ALK-Abelló A/S (Denmark)

5. Genentech Inc. (United States)

6. Prota Therapeutics Pty Ltd. (Australia)

7. Aravax Pty Ltd. (Australia)

8. Camallergy Ltd. (United Kingdom)

9. Stallergenes Greer International AG (Switzerland)

Rising incidence of food allergies is accelerating innovation in immunotherapy and desensitization treatments. The peanut allergy treatment market is evolving through development of targeted biological approaches that reduce allergic response severity. Clinical research advancements are improving treatment safety and efficacy profiles. Expanding therapeutic pipelines are also enhancing long-term management options for patients.

Industry Development/News

Company Name	Date	Key Development
Novartis	Mar-26	Novartis entered a definitive agreement to acquire Excellergy, Inc. in a deal valued at up to $2 billion, expected to close in the second half of 2026. The acquisition adds the lead asset Exl-111, a next-generation anti-IgE antibody, to Novartis' immunology portfolio, strengthening its strategic position in food allergy therapeutics and other IgE-driven disease indications.
DBV Technologies	Jun-26	DBV Technologies initiated the THRIVE Phase 2 clinical study to evaluate the efficacy and safety of the Viaskin Peanut patch in infants aged 6 through 12 months. This expansion of the clinical program into younger populations aims to investigate early intervention strategies for modifying the long-term trajectory of peanut allergy and achieving ad-lib peanut consumption.
Aravax	Apr-26	Aravax strengthened its leadership team with the appointment of new board members Carsten Hellmann and Andrew Oxtoby to support its transition toward Phase 3 clinical development. The company continues to advance its lead peptide-based immunotherapy candidate, PVX108, which is currently undergoing international Phase 2 trials to assess its potential as a safer, disease-modifying treatment for peanut allergy.
Regeneron	Feb-26	Regeneron presented new clinical data highlighting the impact of its immunology portfolio at the AAAAI Annual Meeting. The company continues to study the role of biologics like Dupilumab in managing type 2 inflammation-driven conditions, including analyses of sensitization to common food allergens like peanuts in pediatric populations with atopic dermatitis, supporting its ongoing research into broad allergy therapeutic paradigms.